These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 29929844)

  • 1. Corrigendum to "2-Arylthio-5-iodo pyrimidine derivatives as non-nucleoside HBV polymerase inhibitors" [Bioorg. Med. Chem. 26 (2018) 1573-1578].
    Wang J; Zhang L; Zhao J; Zhang Y; Liu Q; Tian C; Zhang Z; Liu J; Wang X
    Bioorg Med Chem; 2018 Jul; 26(13):3859. PubMed ID: 29929844
    [No Abstract]   [Full Text] [Related]  

  • 2. 2-Arylthio-5-iodo pyrimidine derivatives as non-nucleoside HBV polymerase inhibitors.
    Wang J; Zhang L; Zhao J; Zhang Y; Liu Q; Tian C; Zhang Z; Liu J; Wang X
    Bioorg Med Chem; 2018 May; 26(8):1573-1578. PubMed ID: 29459146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study on 2-arylthio-5-iodo pyrimidine derivatives as novel nonnucleoside inhibitors against hepatitis B virus DNA replication.
    Zhao J; Tu J; Fan N; Chen X; Lu F; Zhang Y; Zhang L; Tian C; Zhang Z; Liu J; Wang X
    Future Med Chem; 2016 May; 8(7):751-63. PubMed ID: 27172826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corrigendum to 'Easy and rapid preparation of benzoylhydrazides and their diazene derivatives as inhibitors of 15-lipoxygenase' [Bioorg. Med. Chem. Lett. 27 (2017) 1649-1653].
    Tirapegui C; Acevedo-Fuentes W; Dahech P; Torrent C; Barrias P; Rojas-Poblete M; Mascayano C
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4218. PubMed ID: 28780158
    [No Abstract]   [Full Text] [Related]  

  • 5. Corrigendum to "Discovery of substituted 6-pheny-3H-pyridazin-3-one derivatives as novel c-Met kinase inhibitors" [Bioorg. Med. Chem. Lett. 24 (2014) 5093-5097].
    Kang ST; Kim EY; Achary R; Jung H; Park CH; Yun CS; Hwang JY; Choi SU; Chae C; Lee CO; Kim HR; Ha JD; Ryu D; Cho SY
    Bioorg Med Chem Lett; 2017 Jul; 27(14):3205. PubMed ID: 28551102
    [No Abstract]   [Full Text] [Related]  

  • 6. Commentary to "The structure of McN-5652" [Bioorg. Med. Chem. 9 (2001) 2105] and to the corrigendum to "The structure of McN-5652" [Bioorg. Med. Chem. 10 (2002) 3368].
    Maryanoff BE
    Bioorg Med Chem; 2002 Oct; 10(10):3367. PubMed ID: 12150884
    [No Abstract]   [Full Text] [Related]  

  • 7. Corrigendum to "Design, synthesis, and bioactivity of dihydropyrimidine derivatives as kinesin spindle protein inhibitors" [Bioorg. Med. Chem. 27 (2019) 115126].
    Tawfik HO; El-Moselhy TF; El-Din NS; El-Hamamsy MH
    Bioorg Med Chem; 2020 Jan; 28(2):115255. PubMed ID: 31862309
    [No Abstract]   [Full Text] [Related]  

  • 8. Corrigendum to "Design, synthesis, and bioactivity of dihydropyrimidine derivatives as kinesin spindle protein inhibitors" [Bioorg. Med. Chem. 27 (2019) 115126].
    Tawfik HO; El-Moselhy TF; El-Din NS; El-Hamamsy MH
    Bioorg Med Chem; 2020 Oct; 28(19):115687. PubMed ID: 32826133
    [No Abstract]   [Full Text] [Related]  

  • 9. Corrigendum to "Antiplasmodial phloroglucinol derivatives from Syncarpia glomulifera" [Bioorg. Med. Chem. 24 (2016) 2544-2548].
    Su Q; Dalal S; Goetz M; Cassera MB; Kingston DGI
    Bioorg Med Chem; 2017 Apr; 25(7):2294. PubMed ID: 28285928
    [No Abstract]   [Full Text] [Related]  

  • 10. Corrigendum to "Design, synthesis and biological evaluation of macrocyclic derivatives as TRK inhibitors" [Bioorg. Med. Chem. Lett. 53 (2021) 128409].
    Li P; Cai S; Zhao T; Xu L; Guan D; Li J; Zhou J; Zhang H
    Bioorg Med Chem Lett; 2022 Jan; 56():128502. PubMed ID: 34906405
    [No Abstract]   [Full Text] [Related]  

  • 11. Corrigendum to "Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors" [Bioorg. Med. Chem. Lett. 31 (2021) 127710].
    Xiang HY; Chen JY; Huan XJ; Chen Y; Gao ZB; Ding J; Miao ZH; Yang CH
    Bioorg Med Chem Lett; 2022 Jan; 56():128501. PubMed ID: 34911648
    [No Abstract]   [Full Text] [Related]  

  • 12. Corrigendum to "Synthesis and biological activity of 2,5-diaryl-3-methylpyrimido[4,5-c]quinolin-1(2H)-one derivatives" [Bioorg. Med. Chem. 15 (2007) 2434-2440].
    Metwally K; Aly O; Aly E; Banerjee A; Ravindra R; Bane S
    Bioorg Med Chem; 2017 May; 25(9):2679. PubMed ID: 28341404
    [No Abstract]   [Full Text] [Related]  

  • 13. Corrigendum to "Synthesis and biological evaluation of novel benzamide derivatives as potent smoothened antagonists" [Bioorg. Med. Chem. Lett. 24/5 (2014) 1426-1431].
    Wu TM; Wang DC; Xiang P; Zhang JN; Sang YX; Lin HJ; Chen J; Xie G; Song H; Zhao YL; Xie YM
    Bioorg Med Chem Lett; 2016 Sep; 26(18):4558. PubMed ID: 27542309
    [No Abstract]   [Full Text] [Related]  

  • 14. Corrigendum to "Discovery of 3,5-dimethylisoxazole derivatives as novel, potent inhibitors for bromodomain and extraterminal domain (BET) family" [Bioorg. Med. Chem. 39 (2021) 116133].
    Fang L; Hu Z; Yang Y; Chen P; Zhou J; Zhang H
    Bioorg Med Chem; 2022 Jan; 54():116574. PubMed ID: 34922820
    [No Abstract]   [Full Text] [Related]  

  • 15. Corrigendum to "Design, synthesis and biological evaluation of imidazopyridazine derivatives containing isoquinoline group as potent MNK1/2 inhibitors" [Bioorg. Med. Chem. 40 (2021) 116186].
    Bu H; Yuan X; Wu H; Zhou J; Zhang H
    Bioorg Med Chem; 2022 Jan; 54():116578. PubMed ID: 34920926
    [No Abstract]   [Full Text] [Related]  

  • 16. Corrigendum to "1-Thiazol-2-yl-N-3-methyl-1H-pyrozole-5-carboxylic acid derivatives as antitumor agents" [Bioorg. Med. Chem. Lett. 27 (2017) 4471-4477].
    Cooper AB; Ciblat S; Shipps G; Levine J; Kostura M; Oza V; Constantineau-Forget L; Dery M; Grand-Maitre C; Bruneau-Latour N; Bellavance E; Patane M; Siddiqui A; Luther M
    Bioorg Med Chem Lett; 2018 Mar; 28(5):985. PubMed ID: 29433931
    [No Abstract]   [Full Text] [Related]  

  • 17. Corrigendum to "Investigation of the structure activity relationship of flufenamic acid derivatives at the human TRESK channel K2P18.1" [Bioorg. Med. Chem. Lett. 26 (2016) 4919-4924].
    Monteillier A; Loucif A; Omoto K; Stevens EB; Lainez S; Saintot PP; Cao L; Pryde DC
    Bioorg Med Chem Lett; 2017 May; 27(9):2082. PubMed ID: 28320618
    [No Abstract]   [Full Text] [Related]  

  • 18. Corrigendum to "Design and synthesis of 1,3-biarylsulfanyl derivatives as new anti-breast cancer agents" [Bioorg. Med. Chem. 19 (2011) 5409-5419].
    Kumar A; Tripathi VD; Kumar P; Gupta LP; Akanksha ; Trivedi R; Bid H; Nayak VL; Siddiqui JA; Chakravarti B; Saxena R; Dwivedi A; Siddiquee MI; Siddiqui U; Konwar R; Chattopadhyay N
    Bioorg Med Chem; 2019 Sep; 27(17):3960-3961. PubMed ID: 31345744
    [No Abstract]   [Full Text] [Related]  

  • 19. Corrigendum to 'Novel carbocyclic nucleoside analogs suppress glomerular mesangial cells proliferation and matrix protein accumulation through ROS-dependent mechanism in the diabetic milieu. II. Acylhydrazone-functionalized pyrimidines' [Bioorg. Med. Chem. Lett. 26 (2016) 1020-1024].
    Bouhadir KH; Koubeissi A; Mohsen FA; Diab El-Harakeh M; Cheaib R; Younes J; Azzi G; Eid AA
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2439. PubMed ID: 31262558
    [No Abstract]   [Full Text] [Related]  

  • 20. Corrigendum to "A cascade synthesis, in vitro cholinesterases inhibitory activity and docking studies of novel Tacrine-pyranopyrazole derivatives" [Bioorg. Med. Chem. Lett. 28 (14) (2018) 2481-2484].
    Derabli C; Boualia I; Abdelwahab AB; Boulcina R; Bensouici C; Kirsch G; Debache A
    Bioorg Med Chem Lett; 2018 Oct; 28(18):3129. PubMed ID: 30119958
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.